Form 4 for BEAM Beam Therapeutics Inc.
Accepted 2025-10-03 00:00:00 ET · period of report 2025-10-01 · accession 0001193125-25-230084 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2025-10-03 | 2025-10-01+ | BEAM | Evans John M. | CEO, Dir | S - Sale+OE | $24.57 | -50.0K | 986.7K | -5% | -$1.23M |
| DMT | 2025-10-03 | 2025-10-01+ | BEAM | Evans John M. | CEO, Dir | M - OptEx | $0.67 | +50.0K | 1.01M | +5% | +$33.5K |
| DMT | 2025-10-03 | 2025-10-01+ | BEAM | Evans John M. | CEO, Dir | M - OptEx | $0.00 | -50.0K | 44.3K | -53% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-01 | S | D | 25,000 | $24.51 | 986,667 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.14 to $24.92, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 2 | Common | Common Stock | 2025-10-02 | S | D | 25,000 | $24.63 | 986,667 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.22 to $25.05, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 3 | Common | Common Stock | 2025-10-02 | M | A | 25,000 | $0.67 | 1,011,667 | D | — | — | |
| 4 | Common | Common Stock | 2025-10-01 | M | A | 25,000 | $0.67 | 1,011,667 | D | — | — | (F2) Includes 418 shares acquired by the Reporting Person under the Beam Therapeutics Inc. ("BEAM") Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2025. |
| 5 | Derivative | Stock Option (Right to Buy) | 2025-10-02 | M | D | 25,000 | $0.00 | 19,336 | D | $0.67 · — to 2028-05-08 | 25,000 Common Stock | (F5) On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, June 30, 2022, and December 31, 2022. |
| 6 | Derivative | Stock Option (Right to Buy) | 2025-10-01 | M | D | 25,000 | $0.00 | 44,336 | D | $0.67 · — to 2028-05-08 | 25,000 Common Stock | (F5) On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, June 30, 2022, and December 31, 2022. |